Evidence map›Paper›PMID 36855409›Full record

ArticleClinical case reports2023

A trial of topiramate for patients with hereditary spinocerebellar ataxia.

Shiroh Miura, Ryusuke Sawada, Akiko Yorita, Hiroshi Kida, Takashi Kamada, Yoshihiro Yamanishi

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Drug repurposing in hereditary ataxia.npj drug discovery · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Shiroh MiuraDepartment of Neurology and Geriatric Medicine Ehime University Graduate School of Medicine Toon Ehime Japan.ORCID https://orcid.org/0000-0003-2409-8404
Ryusuke SawadaDepartment of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kita-ku Okayama Japan.
Akiko YoritaDivision of Respirology, Neurology and Rheumatology, Department of Medicine Kurume University School of Medicine Kurume Fukuoka Japan.
Hiroshi KidaDepartment of Anatomy Fukuoka University School of Medicine Jonan-ku Fukuoka Japan.
Takashi KamadaDepartment of Neurology Fukuoka Sanno Hospital Sawara-ku Fukuoka Japan.
Yoshihiro YamanishiDepartment of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering Kyushu Institute of Technology Iizuka Fukuoka Japan.
Ehime University · JPFukuoka Hospital · JPFukuoka University · JPKurume University · JPKyushu Institute of Technology · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In an open pilot trial, six patients with various hereditary forms of spinocerebellar ataxia (SCA) were assigned to topiramate (50 mg/day) for 24 weeks. Four patients completed the protocol without adverse events. Of these four patients, topiramate was effective for three patients. Some patients with SCA could respond to treatment with topiramate.

Indexed as

drug repositioningspinocerebellar ataxiatopiramate

Identifiers

PMID36855409
PMCPMC9968455
OpenAlexW4322100991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.